T. Brand

发表

Multiple Routes to Oncogenesis Are Promoted by the Human Papillomavirus-Host Protein Network.

Trey Ideker, John Von Dollen, Nevan J Krogan, 2018, Cancer discovery.

Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.

D. Wheeler, M. Iida, I. Horak, 2013, Neoplasia.

AXL IsaLogicalMolecularTarget inHeadandNeck Squamous Cell Carcinoma

R. Salgia, B. Bednarz, M. Lingen, 2015 .

Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation

J. Grandis, N. Jura, J. Gordan, 2018, Oncogene.

Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma.

A. J. van der Kogel, D. Wheeler, M. Iida, 2013, Discovery medicine.

Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer

R. Salgia, D. Wheeler, K. Wisinski, 2014, Molecular Cancer Therapeutics.

Adaptive responses to antibody based therapy.

D. Wheeler, M. Iida, T. Brand, 2016, Seminars in cell & developmental biology.

AXL mediates resistance to cetuximab therapy.

R. Salgia, D. Wheeler, R. Kimple, 2014, Cancer research.

Nuclear EGFR as a molecular target in cancer.

D. Wheeler, M. Iida, T. Brand, 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC.

J. Grandis, Hua Li, Yan Zeng, 2018, Cancer research.

AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma

R. Salgia, B. Bednarz, M. Lingen, 2015, Clinical Cancer Research.

The nuclear epidermal growth factor receptor signaling network and its role in cancer.

D. Wheeler, M. Iida, T. Brand, 2011, Discovery medicine.

Treating PIK3CA and EGFR overexpressing breast cancers with lithium citrate

D. Wheeler, T. Brand, 2011, Cancer biology & therapy.

Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics

V. Bindokas, R. Salgia, Frances E. Lennon, 2013, Cancer biology & therapy.

Targeting Nuclear EGFR: Strategies for Improving Cetuximab Therapy in Lung Cancer

D. Wheeler, M. Iida, T. Brand, 2014 .

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab

D. Wheeler, M. Iida, T. Brand, 2011, Cancer biology & therapy.

KRAS mutant colorectal tumors

D. Wheeler, T. Brand, 2012, Small GTPases.

Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab

D. Wheeler, M. Iida, T. Brand, 2013, Cancer biology & therapy.

The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor

R. Salgia, D. Wheeler, R. Kimple, 2017, Science Signaling.

Yes and Lyn play a role in nuclear translocation of the Epidermal Growth Factor Receptor

D. Wheeler, M. Iida, T. Brand, 2012, Oncogene.

Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab

D. Wheeler, M. Iida, T. Brand, 2011, Cancer biology & therapy.

Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer

Simion I. Chiosea, G. Mills, S. Vandenberg, 2019, The Journal of experimental medicine.

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy

R. Salgia, D. Wheeler, M. Iida, 2014, Molecular Cancer.

Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab

R. Salgia, D. Wheeler, M. Iida, 2016, Molecular Cancer Therapeutics.

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy

R. Salgia, D. Wheeler, M. Iida, 2014, Molecular Cancer.

Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.

Sourav Bandyopadhyay, N. Krogan, J. Grandis, 2018, Cancer research.

Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients

Sourav Bandyopadhyay, J. Grandis, Hua Li, 2016, Clinical Cancer Research.

Combined MET Inhibition and Topoisomerase I Inhibition Block Cell Growth of Small Cell Lung Cancer

R. Salgia, E. Vokes, M. Tretiakova, 2013, Molecular Cancer Therapeutics.

Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.

R. Salgia, KyungMann Kim, D. Wheeler, 2013, Lung cancer.

Small Molecule Therapeutics Combined MET Inhibition and Topoisomerase I Inhibition Block Cell Growth of Small Cell Lung Cancer

R. Salgia, E. Vokes, M. Tretiakova, 2014 .

Cancer Biology and Signal Transduction Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer

R. Salgia, D. Wheeler, K. Wisinski, 2014 .

Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3

D. Wheeler, M. Iida, T. Brand, 2013, PloS one.

AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma

R. Salgia, B. Bednarz, M. Lingen, 2015, Clinical Cancer Research.

Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma

R. Salgia, B. Bednarz, M. Lingen, 2018, Clinical Cancer Research.

Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.

R. Salgia, KyungMann Kim, D. Wheeler, 2013, Lung cancer.